This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

David Bupp To Retire From Neoprobe Board Of Directors

(NYSE Amex: NEOP) Neoprobe’s Board of Directors today announced that former President and Chief Executive Officer, David Bupp, will retire as a Director of Neoprobe Corporation effective January 4, 2012.

“David’s extraordinary vision and commitment to Neoprobe guided it to its position as one of the world’s most innovative radiopharmaceutical development companies,” said Gordon Troup, Chairman of Neoprobe, on behalf of the Board of Directors. “David has made countless contributions to Neoprobe’s success, and he has attracted and inspired Neoprobe’s employees and executive team. We will miss David’s participation in the Board room, but we are pleased that we will continue to have access to his expertise and experience through his existing and ongoing consulting agreement with the Company.”

"Neoprobe has been a major part of my business life for more than 20 years. Leaving the Board is not a decision that I made lightly. However, with the recent filing and acceptance for review of the New Drug Application for Lymphoseek ®, the reactivation of the RIGS ® program and now the in-licensing of a new and exciting product opportunity addressing yet another unmet need in the Alzheimer’s disease space, Neoprobe’s path forward as a precision radiopharmaceutical diagnostics company is very clear. I am pleased with my contributions to those efforts and feel now is an appropriate time for me to leave the Company as a Director with the launch of Navidea Biopharmaceuticals," said David Bupp. "I leave the Company in the hands of a very capable and energetic management team and Board. I am confident that Neoprobe is poised for the success I have always known it could achieve.”

About Neoprobe (Navidea Biopharmaceuticals)

Neoprobe Corporation (NYSE Amex: NEOP) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Neoprobe is actively developing three radiopharmaceutical agent platforms – Lymphoseek ®, AZD4694 and RIGScan TM CR – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and ultimately patient care. Neoprobe’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.26 -0.77%
FB $101.50 2.00%
GOOG $684.03 0.87%
TSLA $163.06 10.00%
YHOO $27.10 1.00%


Chart of I:DJI
DOW 15,914.74 -99.64 -0.62%
S&P 500 1,851.86 -0.35 -0.02%
NASDAQ 4,283.5920 +14.8290 0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs